Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.80 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.80 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.80 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388745 | 0.91 | RXRA (0.67) | RXRANR1H2NR1H3RIPK3MAPK14 | |
| SCHEMBL2387908 | 0.89 | RXRA (1.00) | RXRANR1H2NR1H3MAPK14GRM2 | |
| SCHEMBL14944245 | 0.88 | RXRA (0.60) | RXRANR1H2NR1H3GRM2KDM4E | |
| SCHEMBL14214400 | 0.88 | RXRA (0.84) | RXRANR1H2NR1H3MAPK14KDM4E | |
| SCHEMBL2262731 | 0.88 | RXRA (0.83) | RXRANR1H2NR1H3MAPK14KDM4E | |
| SCHEMBL2388573 | 0.88 | RXRA (0.67) | RXRANR1H2NR1H3RIPK3MAPK14 | |
| SCHEMBL14184000 | 0.87 | NR1H2 (0.71) | RXRANR1H2NR1H3RIPK3MAPK14 | |
| SCHEMBL2390450 | 0.87 | RXRA (0.70) | RXRANR1H2NR1H3RIPK3MAPK14 | |
| SCHEMBL2390069 | 0.86 | RXRA (0.78) | RXRANR1H2NR1H3MAPK14KDM4E | |
| SCHEMBL2387246 | 0.86 | RXRA (0.91) | RXRANR1H2NR1H3RIPK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.